مالطا - الإنجليزية - Malta Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - paricalcitol - solution for injection - paricalcitol 2 µg/ml - calcium homeostasis

مالطا - الإنجليزية - Malta Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - paricalcitol - solution for injection - paricalcitol 5 µg/ml - calcium homeostasis

مالطا - الإنجليزية - Malta Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - paricalcitol - solution for injection - paricalcitol 5 µg/ml - calcium homeostasis

مالطا - الإنجليزية - Malta Medicines Authority

accord healthcare limited - paricalcitol - solution for injection - paricalcitol 2 µg/ml - calcium homeostasis

مالطا - الإنجليزية - Malta Medicines Authority

accord healthcare limited - paricalcitol - solution for injection - paricalcitol 5 µg/ml - calcium homeostasis

مالطا - الإنجليزية - Malta Medicines Authority

accord healthcare limited - paricalcitol - solution for injection - paricalcitol 5 µg/ml - calcium homeostasis

إسرائيل - الإنجليزية - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol - solution for injection - paricalcitol 5 mcg/ml - paricalcitol - paricalcitol - paricalcitol is indicated for the prevention and treatment of secondary hyperparathyrodism associated with chronic renal failure.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

cardinal health - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol 1 ug

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

abbvie inc. - paricalcitol (unii: 6702d36og5) (paricalcitol - unii:6702d36og5) - paricalcitol 2 ug in 1 ml - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (ckd) on dialysis. zemplar is contraindicated in patients with: - hypercalcemia [see warnings and precautions ( 5.1 )] - vitamin d toxicity [see warnings and precautions ( 5.1 )] - known hypersensitivity to paricalcitol or any of the inactive ingredients in zemplar. hypersensitivity adverse reactions have been reported [e.g., angioedema (including laryngeal edema) and urticaria] [see adverse reactions ( 6.2 )] . risk summary limited data with zemplar in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. there are risks to the mother and fetus associated with chronic kidney disease in pregnancy (see clinical considerations ) . in animal reproduction studies, slightly increased embryofetal loss was observed in pregnant rats and rabbits administered paricalcitol intravenously during the period of organogenes

إسرائيل - الإنجليزية - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol - capsules soft - paricalcitol 1 mcg - paricalcitol - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.